Preclinical studies have shown that combining CAR-T cells targeting EGFRvIII with anti-PD-1 or anti-PD-L1 antibodies results in significant tumor regression in GBM models, indicating that checkpoint blockade can potentiate CAR-T cell activity (211). Here, CD274 is linked to neoplasm.